抗胸腺细胞球蛋白对不同供者类型急性白血病缓解期异基因造血干细胞移植的影响
该回顾性分析纳入2008至2015年接受异基因造血干细胞移植的急性白血病患者6617例,其中279例接受兔抗胸腺细胞球蛋白(胸腺球蛋白),6338例未接受。多因素分析显示,胸腺球蛋白仅对1个等位基因不合无关供者移植改善无GVHD/无复发生存并降低GVHD及非复发死亡,对脐血移植则与总生存下降相关。
要点
- 1个等位基因不合无关供者移植中,胸腺球蛋白改善GRFS并降低II-IV级aGVHD、广泛型cGVHD及NRM。
- 脐血移植中,胸腺球蛋白与总生存下降及NRM增加相关。
- 1个抗原不合亲缘供者及全合无关供者移植中,胸腺球蛋白对生存无影响。
核心结论
- 仅在1个等位基因不合无关供者移植中,胸腺球蛋白因降低急慢性GVHD且不增加NRM或疾病复发而有益;脐血移植不推荐使用胸腺球蛋白。
研究设计与样本
- 回顾性分析2008至2015年接受异基因造血干细胞移植的急性白血病患者6617例,其中胸腺球蛋白组279例、无胸腺球蛋白组6338例。
- 存活者中位随访时间为1081天。
- 患者分为5组:脐血1915例、全合亲缘供者1772例、1个抗原不合亲缘供者225例、全合无关供者1742例、1个等位基因不合无关供者963例。
主要发现
- 脐血移植中,胸腺球蛋白与总生存下降相关(HR 1.403;P=0.054),与GRFS下降相关(HR 1.458;P=0.053),与非复发死亡增加相关(HR 1.608;P=0.03)。
- 1个等位基因不合无关供者移植中,胸腺球蛋白改善GRFS(HR 0.515;P<0.01),降低II-IV级aGVHD(HR 0.576;P<0.01)、广泛型cGVHD(HR 0.460;P=0.02)及NRM(HR 0.545;P=0.03)。
- 1个抗原不合亲缘供者及全合无关供者移植中,胸腺球蛋白对生存无影响。
关键数值与推荐
- 脐血移植中,胸腺球蛋白组总生存HR 1.403(P=0.054),GRFS HR 1.458(P=0.053),NRM HR 1.608(P=0.03)。
- 1个等位基因不合无关供者移植中,胸腺球蛋白组GRFS HR 0.515(P<0.01),II-IV级aGVHD HR 0.576(P<0.01),广泛型cGVHD HR 0.460(P=0.02),NRM HR 0.545(P=0.03)。
临床怎么用
- 作者认为,在1个等位基因不合无关供者移植的预处理中使用胸腺球蛋白有益,因降低急慢性GVHD且不增加NRM或疾病复发。
- 作者不推荐在脐血移植中使用胸腺球蛋白。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antithymocyte globulin (ATG) is widely used to reduce acute graft-versus-host disease (aGVHD) and chronic GVHD (cGVHD). To clarify the different impacts of ATG for conditioning across different donor types, we retrospectively analyzed patients with acute leukemia (n = 6617) who underwent hematopoietic stem cell transplantation between 2008 and 2015 with ATG (n = 279) or without ATG (n = 6338). Because thymoglobulin is the only ATG drug approved for GVHD prophylaxis in Japan since September 2008, we included thymoglobulin alone in the present analysis. The survivors' median follow-up time was 1081 days. Patients were categorized into 5 groups: cord blood (CB; n = 1915), matched related donor (n = 1772), 1-antigen mismatched related donor (1-MMRD; n = 225), matched unrelated donor (MUD; n = 1742), and 1-allele mismatched unrelated donor (1-MMUD; n = 963). In multivariate analysis, ATG decreased overall survival (hazard ratio [HR], 1.403; P = .054) and GVHD-free/relapse-free survival (GRFS) (HR, 1.458; P = .053) in association with increased nonrelapse mortality (NRM) (HR, 1.608; P =03) with CB, whereas it improved GRFS (HR, 0.515; P < .01) and decreased grades II to IV aGVHD (HR, 0.576; P < .01), extensive cGVHD (HR, 0.460; P = .02), and NRM (HR, 0.545; P = .03) with 1-MMUD. ATG did not impact survival with 1-MMRD and MUD. The use of ATG in conditioning is beneficial due to the reduction in acute/chronic GVHD without increasing NRM or disease relapse only in 1-MMUD transplantation. On the other hand, ATG is not recommended for CB transplantation.
引用
- Wakamatsu M, Terakura S, Ohashi K, et al. Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors. Blood Adv. 2019. PMID: 30626574. doi:10.1182/bloodadvances.2018025643
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。